Interleukin-1 (IL-1), a pro-inflammatory chemokine, can promote the proliferation and differentiation of tumor cells via interactions with specific receptors on tumor cell membrane surfaces. 6 IL-1RA, IL-1α, and IL-1β are all members of the interleukin-1 family. IL-1α
and IL-1β bind to the same receptor and perform similar biological activities, such as promoting tumor growth and metastasis via enhanced angiogenesis. This activity is performed by the regulation of the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF). 7 IL-1RA is a pan-physiological inhibitor of IL-1 that prevents the activation of IL-1 receptors by inhibiting IL-1 binding to its receptors. IL-1 RA is a glycosylated protein of [23] [24] [25] KDa. Cloned IL-1RA DNA contains an open reading frame encoding F I G U R E 1 Clinical study: A, The expression of IL-1RA was detected by Western blotting cancerous and paracancerous tissues from eight groups of patients. The results show that the expression of IL-1RA in esophageal cancer tissues decreased compared to paracancerous tissue. B, Immunohistochemical staining of 76 tumor samples was performed to investigate the expression of IL-1RA in paracancerous tissues and adjacent tissues and showed that the expression of IL-1RA was significantly decreased in esophageal cancer patients (P = 0.000). C, The expression of the IL-1RN gene in esophageal cancer and adjacent tissues was detected by RT-PCR. 
| Western blot analysis
Tissues or cells were lysed in Western & IP cell lysis buffer (Beyotime) with PMSF (Amresco) for 30 minutes on ice at 4°C
followed by centrifugation at 12 000 × g for 15 minutes at 4°C.
The supernatants were collected, and the total protein concentration was measured using the BCA Protein Assay Kit (Thermo Scientific). Equimolar amounts of protein were loaded into each well and separated with 12% SDS-PAGE. Then, proteins were transferred to a 0.45-μm PVDF membrane (Amersham Hybond, GE Healthcare), which was blocked in 2% bovine serum albumin (Amresco) prior to overnight incubation overnight at 4°C with the following primary antibodies: rabbit anti-IL-1RA, rabbit anti-IL-1α
(1:1000), mouse anti-β-actin (1:2000; Cell Signaling Technology), and VEGF-A polyclonal antibody (1:1000, A41552). After three washes in TBST buffer lasting 10 minutes per wash, the membrane was incubated with secondary antibodies for 1 hour at room temperature. The blots were developed using enhanced chemiluminescence (Lulong Biotech).
| RNA extraction and real-time quantitative PCR
Total RNA was extracted from cultured cells or frozen tissues using
TRIzol reagent (Ambion), and 1 mg RNA was reverse transcribed using miScript Reverse Transcription Kit (Qiagen) for first complementary DNA strand synthesis. Quantitative PCR was performed using SYBR Premix EX Taq kit (Takara). Specific primers were used to detect the relative mRNA expression of IL-1RA by the 2-△△ Ct method. The expression level was normalized against endogenous GAPDH. All the primers were designed by BioSune Biotechnology
Co., Ltd. (Shanghai).
| Cell lines
Human EC cell lines KYSE410 and EC9706 were purchased from Hunan Fenghbio Biological Ltd, China. The cells were grown in RPMI-DMEM (Gibco) medium supplemented with 10% FBS (Gibco) and incubated at 37°C in an atmosphere of 5% CO 2 .
| Plasmids and generation of stable ec cell lines
The opening reading frame of the human IL-1RA gene was PCR-amplified and cloned into the lentivirus expression vector pCDH-CMV-MCS-EF1-RFP-Puro (System Biosciences). Either a recombinant plasmid or an empty vector was co-transfected with packaging plasmids pMDL, pVSVG, and pRev into 293T cells. The supernatants were collected at 48 hours post-transfection and used to infect KYSE410 and EC9706 cells cultured in 6-cm dishes.
Puromycin-resistant clones were expanded into cell lines as IL-1RA
overexpressing cells (KYSE410-PIL-1RA or EC9706-IL-1RA) or empty control cells (KYSE410-pCDH or EC9706-pCDH). The protein expression levels of IL-1RA were evaluated by Western blot analysis.
| Wound-healing assay
Transfected cells were grown to 100% confluence in six-well plates.
The cell layers were scratched using a 20-μL tip to form wound gaps, washed three times with phosphate-buffered saline (PBS), and photographed at different time points. The cells were counted using a scale label to determine movement activity away from the original scratch location 48 hours after knockdown.
| Cell invasion assay
Cell invasion assays were performed using transwell membranes 
| Colony formation assay
Stably transfected cells were harvested and seeded in six-well plates at a density of 1 × 10 3 cells/well. After 2 weeks, the cells were fixed in 3% methanol for 30 minutes and stained with 1% crystal violet for 10 minutes. The number of visible colonies was then counted using a phase contrast microscope.
F I G U R E 2 Cell study A, Western blotting (WB) detected the expression of IL-1RA and IL-1α in different esophageal squamous carcinoma cells. IL-1RA is expressed in all esophageal squamous carcinoma cells, and IL-1α is expressed at low levels in EC9706 cells. B, WB verified cells stably overexpressing IL-1RA in esophageal squamous cell carcinoma. Changes in VEGF-A expression were observed to correlate with the change in IL-1RA expression. The results showed that for KYSE410 cells, the expression of VEGF-A decreased with an increase in IL-1RA expression, while for EC9706 cells, this result was not the case. In this case, the expression was not obvious
| Cell proliferation assay
Cells in the logarithmic growth phase were planted in 96-well plates at a density of 4 × 10 3 cells/well. The next day, a Cell Counting Kit-8
(CCK-8; Donjido, Kumamoto, Japan) was used according to the manufacturer's instructions. The optical density (OD) was detected using a microplate reader (BioTek, VT, USA) at a fixed time each day for 6 days.
| Statistical analysis
Statistical analysis was performed using SPSS 21.0 for Windows.
All data used for the analysis were expressed as the means ± SDs from three independent experiments. The association between IL-1RA expression and the clinicopathological parameters was analyzed using Pearson's chi-square test and Spearman's rank-order correlation. Survival curves were plotted using Kaplan-Meier analysis. Differences were considered significant when P-values were <0.05.
| RE SULTS

| Downregulation of IL-1RA in EC is correlated with poor prognosis
Seventy-six tumor samples were analyzed by immunohistochemistry (IHC) to detect the prognostic value of IL-1RA expression. As shown in representative Figure 1 and Table 1 , IL-1RA expression was significantly lower in the EC tumors than in the adjacent normal tissues.
Western blot analysis and genetic testing also confirmed the expression of both IL-1RA protein ( Figure 1A ) and mRNA ( Figure 1B (Table 1 ). After confirming that IL-1RA expression was downregulated in EC (P = 0.003),
Kaplan-Meier analysis was used to investigate the relationship F I G U R E 3 A, Cell scratch test to detect cell migration ability. IL-1RA expression had no significant effect on cell migration ability. B, Cell plate clone assay to detect cell proliferation ability. IL-1RA overexpression significantly reduced the proliferation of KYSE410 cells, but no effect was observed for the EC9706 cells. C, CCK-8 assay to detect cell proliferation function. IL-1RA overexpression significantly reduced the proliferation of KYSE410 cells (P＜0.05), but no effect was observed for EC9706 cells between IL-1RA expression assessed by IHC and patient outcome.
As shown in Figure 1D , patients with low IL-1RA-expressing tumors had significantly shorter 5-year survival than patients with high IL-1RA-expressing tumors (P = 0.044). Altogether, these results suggest that IL-1RA may be a tumor suppressor and that a decrease in IL-1RA expression can promote the progression of EC.
| IL-1RA overexpression suppressed EC cell proliferation
To investigate the biological functions of IL-1RA in regulating ESCC, we first detected the expression of IL-1RA and IL-1α in EC cell lines (Figure 2A) . Then, we used gene overexpression strategies to specifically increase the amount of IL-1RA protein in the EC cell lines KYSE410 and EC9706. Stable overexpression of IL-1RA in these cells was confirmed by Western blot analysis ( Figure 2B ). The overexpression of IL-1RA did not produce any changes in the rate of migration of KYSE410 and EC9706 cells in vitro, as evaluated by wound-healing assay ( Figure 2C ). Then, we compared the effect of IL-1RA on cell proliferation using CCK-8 and colony formation assays. As shown in Figure 2D and Figure 2E , proliferation was suppressed by overexpression of IL-1RA in KYSE410 cells, which express IL-1α. No difference was observed in EC9706 cells.
| IL-1RA suppressed ESCC proliferation via the IL-1α/VEGF signaling pathway
To understand the molecular mechanisms underlying IL-1RA-induced inhibition of EC proliferation, we assessed the expression 
| D ISCUSS I ON
The results reported in this study provide evidence that the ex- The development of new blood vessels is a key pathway in the progression of solid tumors. Angiogenesis not only provides the tumor with oxygen and essential nutrients but also promotes the spread and proliferation of cancer cells. 14 Angiogenesis is a complex, multi-step process involving extracellular matrix remodeling, migration and proliferation of endothelial cells, and capillary formation. 15 VEGF is the prototypical angiogenic stimulating molecule that has been implicated in several steps of the angiogenic process. Increasing VEGF expression is directly proportional to increasing tumor growth and metastasis by promoting angiogenesis and increasing vascular permeability. 16 The role of VEGF in angiogenesis was further confirmed by the effects of hypoxia and several indirect effects of proangiogenic factors, which were able to further increase the synthesis of VEGF. 17, 18 It is important that VEGF has also been associated with tumor progression by stimulating angiogenesis in human esophageal carcinoma. 19, 20 IL-1RA is a member of the interleukin-1 family. In contrast to IL-1α and IL-1β, which promote tumor progression through inflammation, IL-1RA possesses a tumor-suppressing effect by blocking the binding of IL-1 to its target receptor [11, 12] . Increasing 
